Key result
Epoprostenol infusion and tolazoline bolus injection produced similar pulmonary and systemic vasodilatation in children with pulmonary hypertension, with no significant differences.
Why the study?
Does infusion of epoprostenol improve haemodynamic effects compared to bolus injection of tolazoline in children with pulmonary hypertension?
Does infusion of epoprostenol improve haemodynamic effects compared to bolus injection of tolazoline in children with pulmonary hypertension?
Epoprostenol provides similar haemodynamic benefits to tolazoline in children with pulmonary hypertension but may be more suitable for repeated dosing due to a better safety profile.
Answers are grounded in this paper and cite their sources.
Similar effects in this pediatric cohort; leaves open need for randomized trials on dosing and safety.
The haemodynamic effects of infusion of epoprostenol (prostacyclin) and bolus injection of tolazoline were compared in a crossover study in 11 children with pulmonary hypertension caused by pulmonary vascular disease. The children were studied during cardiac catheterisation, while they were anaesthetised, paralysed, and ventilated with 100% oxygen. The order of drug administration was not randomised because tolazoline has a half life of hours whereas epoprostenol has a half life of a few minutes. Both drugs caused pulmonary and systemic vasodilatation, and there were no significant differences between the two. The 95% confidence intervals suggest that tolazoline did not have a clinically important haemodynamic advantage over epoprostenol. Previous reports suggest that serious side effects are common when tolazoline is used in repeated doses; epoprostenol has only a few minor side effects that are rapidly reversible when the infusion is stopped. Epoprostenol is more expensive than tolazoline but this study suggests that epoprostenol is a more suitable pulmonary vasodilator if more than a single dose is required.
No takes yet. Share an insight, caveat, or question.
Bush et al. (1988) studied Pulmonary hypertension caused by pulmonary vascular disease (n=11). Epoprostenol (prostacyclin) vs. Tolazoline was evaluated on Haemodynamic effects (pulmonary and systemic vasodilatation). Epoprostenol infusion and tolazoline bolus injection produced similar pulmonary and systemic vasodilatation in children with pulmonary hypertension, with no significant differences.
Synapse has enriched 10 related papers. Consider them for comparative context: